• Participants compared Bitcoin alternatives Litecoin, PPCoin (touted as ASIC-proof and lower-power), and Zerocoin (a privacy add-on) to identify technical improvements beyond Bitcoin’s original design.

• A DIY gene-therapy self-experiment was outlined: electroporation of a follistatin-expressing plasmid into arm muscle to boost muscle mass, with plans to escalate to an Fc-fusion construct if the first trial is ineffective.

• The group debated whether chronic-virus immune-evasion tactics (e.g., CMV disruption of MHC-I presentation) could be repurposed for safe, repeatable gene therapy, concluding that poor in-vivo targeting, not immunology, is the primary clinical barrier.

• Licensing worries surfaced around NCBI/GenBank data: participants questioned whether sequence data are truly public domain and warned that patent holders might force redaction or downstream litigation.

• Eureka Genomics was noted as aiming to undercut microarray prices for SNP genotyping while assembling client genomes for universities, raising concerns about un-audited upstream data licenses.

• The London biohacking group’s 2011 shift from diy-bio.eu to lhs-biohacking@lists.kentgeek.org was cited as an example of the ongoing fragmentation of open-science communication channels.

• The EFF’s new policy brief urging the USPTO to require source-code disclosure for software patents was shared (PDF link provided).

• Recommended resources included the interactive visualization “donottouch.org” for human–machine interaction data and the Coursera “Computational Neuroscience” course as an introductory primer.